SOD1 and amyotrophic lateral sclerosis: Although the Toferesen clinical trial showed a decrease of SOD1 and NfL, a biomarker of neuronal degeneration, there were no measurable clinical improvements (25), suggesting that additional therapeutic measures may need to be implemented in people with SOD1 ALS.